You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor (CAR)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

Not yet recruiting
  • Follicular Lymphoma
  • Axicabtagene Ciloleucel
  • +5 more
  • (no location specified)
Sep 21, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19

Recruiting
  • Lymphoblastic Leukemia
  • +5 more
  • Anti-CD19 CAR T-cells
  • Singapore, Singapore
  • +1 more
Dec 4, 2022

Metastatic Castration-resistant Prostate Cancer Trial (TmPSMA-02)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TmPSMA-02
  • (no location specified)
Aug 3, 2022

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem

Not yet recruiting
  • Hematologic Malignancy
  • +5 more
  • autologous hematopoietic stem cells added to planned CAR T
  • Los Angeles, California
    Cedars-Sinai Medical Center
May 31, 2023

Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma Trial in Nashville (Telemedicine Visit, Vital sign measurements,

Recruiting
  • Large B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Telemedicine Visit
  • +3 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Sep 28, 2022

Lymphoma, Leukemia, Myeloma Trial in Tampa (Resistance Training, Aerobic Exercise)

Recruiting
  • Lymphoma
  • +2 more
  • Resistance Training
  • Aerobic Exercise
  • Tampa, Florida
    Moffitt Cancer Center
Feb 28, 2023

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Trial (TmPSMA-02 CAR T Cells)

Not yet recruiting
  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
  • TmPSMA-02 CAR T Cells
  • (no location specified)
Sep 13, 2023

B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

Active, not recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Maywood, Illinois
    Loyola University
Aug 11, 2022

Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

Active, not recruiting
  • Multiple Myeloma
  • Infusion of MCARH109 T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 5, 2022

Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • anti-CD19 CAR NK cells (KN5501)
  • Shanghai, China
    Changhai Hospital
Aug 25, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • UCD19 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Hepatocellular Carcinoma Trial in Shanghai (Ori-C101)

Recruiting
  • Hepatocellular Carcinoma
  • Ori-C101
  • Shanghai, China
    Zhongshan Hospital Fudan University
Dec 21, 2022

Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • GD2 CAR T cells
  • (no location specified)
Sep 15, 2022

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022